Marcaine
Diverticulitis Of Colon
Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Illinois College of Medicine at Peoria
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02958566CT.gov Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diverticulitis Of Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Marcaine (this asset) | University of Illinois College of Medicine at Peoria | Approved | B · 61 |
| Lidocaine | University of Illinois College of Medicine at Peoria | P4 | B |
| (±)-Tramadol | University of Illinois College of Medicine at Peoria | P4 | B |
| Dilaudid | University of Illinois College of Medicine at Peoria | P4 | B |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | University of Illinois College of Medicine at Peoria | P4 | B |
| Nepenthe | University of Illinois College of Medicine at Peoria | P4 | B |
| Oxycodone Hydrochloride, Hydrocodone- | University of Illinois College of Medicine at Peoria | P4 | B |
| Fentanyl | University of Illinois College of Medicine at Peoria | P4 | B |
| Orphenadrin | University of Illinois College of Medicine at Peoria | P4 | B |
+3 more in the Diverticulitis Of Colon cohort
Other indications for Marcaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BBB · 74 |
| Neuralgia | — | P4 | BBB · 74 |
| Chronic Pain Syndrome | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- LidocaineUniversity of Illinois College of Medicine at PeoriaB
- (±)-TramadolUniversity of Illinois College of Medicine at PeoriaB
- DilaudidUniversity of Illinois College of Medicine at PeoriaB
- (±)-2-(O-Chlorophenyl)-2-(Methylamino)CyclohexanoneUniversity of Illinois College of Medicine at PeoriaB
- NepentheUniversity of Illinois College of Medicine at PeoriaB
Citation
Floatz Terminal. Marcaine in Diverticulitis Of Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1-butyl-26-pipecoloxylidide-monohydrochloride-diverticulitis-of-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →